387 related articles for article (PubMed ID: 35936736)
1. A novel cuproptosis-related prognostic lncRNA signature and lncRNA MIR31HG/miR-193a-3p/TNFRSF21 regulatory axis in lung adenocarcinoma.
Mo X; Hu D; Yang P; Li Y; Bashir S; Nai A; Ma F; Jia G; Xu M
Front Oncol; 2022; 12():927706. PubMed ID: 35936736
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
3. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
4. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
5. The LncRNA NEAT1 Accelerates Lung Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a Competitive Endogenous RNA.
Xiong DD; Li ZY; Liang L; He RQ; Ma FC; Luo DZ; Hu XH; Chen G
Cell Physiol Biochem; 2018; 48(3):905-918. PubMed ID: 30036873
[TBL] [Abstract][Full Text] [Related]
6. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
Wang X; Jing H; Li H
Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel intermittent hypoxia-related prognostic lncRNA signature and the ceRNA of lncRNA GSEC/miR-873-3p/EGLN3 regulatory axis in lung adenocarcinoma.
Liu P; Zhou L; Chen H; He Y; Li G; Hu K
PeerJ; 2023; 11():e16242. PubMed ID: 37842058
[TBL] [Abstract][Full Text] [Related]
8. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
10. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive bioinformatics analysis to identify a novel cuproptosis-related prognostic signature and its ceRNA regulatory axis and candidate traditional Chinese medicine active ingredients in lung adenocarcinoma.
Wang S; Xing N; Meng X; Xiang L; Zhang Y
Front Pharmacol; 2022; 13():971867. PubMed ID: 36110528
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
15. Identification Invasion-Related Long Non-Coding RNAs in Lung Adenocarcinoma and Analysis of Competitive Endogenous RNA Regulatory Networks.
Mao Y; Cai F; Jiang T; Zhu X
Int J Gen Med; 2023; 16():1817-1831. PubMed ID: 37213476
[TBL] [Abstract][Full Text] [Related]
16. Identification and integration analysis of a novel prognostic signature associated with cuproptosis-related ferroptosis genes and relevant lncRNA regulatory axis in lung adenocarcinoma.
Wang T; Jiang X; Lu Y; Ruan Y; Wang J
Aging (Albany NY); 2023 Mar; 15(5):1543-1563. PubMed ID: 36881404
[TBL] [Abstract][Full Text] [Related]
17. Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach.
Yang L; Cui Y; Liang L; Lin J
Thorac Cancer; 2023 Jun; 14(16):1451-1466. PubMed ID: 37076991
[TBL] [Abstract][Full Text] [Related]
18. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
19. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and personalized treatment prediction in lung adenocarcinoma: An
Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z
Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
